$ANAB SEC Filings

Filed On	Filing
02 Oct 2026	Form 4: Renton Hollings, Director Received 5,000 shares by exercise or conversion ($90.2K) · Sold 5,000 shares ($249K)
01 Oct 2026	144
21 Sep 2026	10-KT
21 Sep 2026	8-K: Financial Statements and Exhibits Jemperli global net sales of $644 million (£480 million) for the six months ended June 30, 2026, representing 34% year-over-year growth
17 Sep 2026	Form 4: Orwin John A, Director Received 1,300 shares by exercise or conversion
14 Aug 2026	SCHEDULE 13G/A
11 Aug 2026	8-K: Submission of Matters to a Vote of Security Holders
07 Aug 2026	Form 4: Lizzul Paul F., Chief Medical Officer Granted 16,667 Performance Stock Units
07 Aug 2026	Form 4: Faga Daniel, Director Granted 53,334 Performance Stock Units
30 Jul 2026	8-K: Regulation FD Disclosure
13 Jul 2026	144
30 Jun 2026	144
29 Jun 2026	144
29 Jun 2026	ARS
29 Jun 2026	DEFA14A
29 Jun 2026	Proxy statement: annual meeting on August 11, 2026 CEO pay $6.1M, down 55% · say-on-pay vote
26 Jun 2026	144
22 Jun 2026	8-K: Entry into a Material Definitive Agreement
17 Jun 2026	144
17 Jun 2026	Form 4: Schmid John P., Director Received 6,030 shares by exercise or conversion

Comments